BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 24682919)

  • 1. Evaluation of selenium, redox status and their association with plasma amyloid/tau in Alzheimer's disease.
    Krishnan S; Rani P
    Biol Trace Elem Res; 2014 May; 158(2):158-65. PubMed ID: 24682919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The neurofilament heavy chain (NfH) in the cerebrospinal fluid diagnosis of Alzheimer's disease.
    Brettschneider J; Petzold A; Schottle D; Claus A; Riepe M; Tumani H
    Dement Geriatr Cogn Disord; 2006; 21(5-6):291-5. PubMed ID: 16484807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia.
    Jia JP; Meng R; Sun YX; Sun WJ; Ji XM; Jia LF
    Neurosci Lett; 2005 Jul 22-29; 383(1-2):12-6. PubMed ID: 15936505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neprilysin-like activity correlates with CSF-Tau and phospho-tau in patients with Alzheimer's disease.
    Sorensen KC; Simonsen AH; Holmetoft UB; Hasselbalch SG; Heegaard NH
    J Alzheimers Dis; 2013; 37(2):379-87. PubMed ID: 23948879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
    Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
    J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiplex immunoassay measurement of amyloid-β
    Vogelgsang J; Shahpasand-Kroner H; Vogelgsang R; Streit F; Vukovich R; Wiltfang J
    Exp Brain Res; 2018 May; 236(5):1241-1250. PubMed ID: 29480353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSF tau protein and beta-amyloid (1-42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population.
    Kapaki E; Paraskevas GP; Zalonis I; Zournas C
    Eur J Neurol; 2003 Mar; 10(2):119-28. PubMed ID: 12603286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevation of the Plasma Aβ40/Aβ42 Ratio as a Diagnostic Marker of Sporadic Early-Onset Alzheimer's Disease.
    Kim HJ; Park KW; Kim TE; Im JY; Shin HS; Kim S; Lee DH; Ye BS; Kim JH; Kim EJ; Park KH; Han HJ; Jeong JH; Choi SH; Park SA
    J Alzheimers Dis; 2015; 48(4):1043-50. PubMed ID: 26444752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease.
    Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Kim SE; Lee BS; Kim GJ; Yu JS; Lim K; Kang SM; Park YH; Youn YC; An SSA; Kim S
    Alzheimers Res Ther; 2017 Dec; 9(1):98. PubMed ID: 29246249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
    Ibach B; Binder H; Dragon M; Poljansky S; Haen E; Schmitz E; Koch H; Putzhammer A; Kluenemann H; Wieland W; Hajak G
    Neurobiol Aging; 2006 Sep; 27(9):1202-11. PubMed ID: 16085339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid profile of amyloid β42 (Aβ42), hTau and ubiquitin in North Indian Alzheimer's disease patients.
    Kandimalla RJ; S P; Bk B; Wani WY; Sharma DR; Grover VK; Bhardwaj N; Jain K; Gill KD
    Neurosci Lett; 2011 Jan; 487(2):134-8. PubMed ID: 20599474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSF tau, Aβ42, and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease.
    Aerts MB; Esselink RA; Claassen JA; Abdo WF; Bloem BR; Verbeek MM
    J Alzheimers Dis; 2011; 27(2):377-84. PubMed ID: 21841257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of plasma biomarkers in early diagnosis of Alzheimer's disease.
    Wang T; Xiao S; Liu Y; Lin Z; Su N; Li X; Li G; Zhang M; Fang Y
    Int J Geriatr Psychiatry; 2014 Jul; 29(7):713-9. PubMed ID: 24318929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau.
    Lewczuk P; Esselmann H; Otto M; Maler JM; Henkel AW; Henkel MK; Eikenberg O; Antz C; Krause WR; Reulbach U; Kornhuber J; Wiltfang J
    Neurobiol Aging; 2004 Mar; 25(3):273-81. PubMed ID: 15123331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
    Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L
    Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults.
    Paternicò D; Galluzzi S; Drago V; Bocchio-Chiavetto L; Zanardini R; Pedrini L; Baronio M; Amicucci G; Frisoni GB
    Alzheimers Dement; 2012 Nov; 8(6):520-7. PubMed ID: 22677492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature.
    Frankfort SV; Tulner LR; van Campen JP; Verbeek MM; Jansen RW; Beijnen JH
    Curr Clin Pharmacol; 2008 May; 3(2):123-31. PubMed ID: 18700307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of CSF-Chlamydia pneumoniae, CSF-tau, and CSF-Abeta42 in Alzheimer's disease and vascular dementia.
    Paradowski B; Jaremko M; Dobosz T; Leszek J; Noga L
    J Neurol; 2007 Feb; 254(2):154-9. PubMed ID: 17318713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.